2024-02-13 10:06:50 ET
With %Biotech stocks finding tremendous success in recent months, it’s no wonder why everyone wants to get in on the action, including institutional investors. After yesterday’s market close, a Form SC 13G (Statement of acquisition of beneficial ownership by individuals) was filed on behalf of Bigger capital Fund GP, LLC, which showed that the group reported a 9.9% stake in %BiodexaPharmaceuticals (Nasdaq: BDRX).
It didn’t take long for traders to want to get their hands on this micro cap, with shares currently bid up at $1.92/share (+32.41% implied open for sellers) at the time of writing. It should be an exciting session for this biotech!
Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The Company is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. It has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.